MedTrace Logo

Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services

NCT01115361 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2012-03-29

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of an intervention, which is designed to increase contraceptive prevalence among postpartum women attending vaccination services who desire to either space or limit their pregnancies, thus reducing unmet contraceptive need in this population.

Conditions

  • Contraception

Interventions

BEHAVIORAL

Family planning for postpartum women

A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period. B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women. C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services. D.Convenient offer of FP services to women attending vaccination services for their infants.

Sponsors & Collaborators

  • Ministry of Health, Rwanda

    collaborator OTHER_GOV

  • FHI 360

    lead OTHER

Principal Investigators

  • Lisa S Dulli, PhD, MHS · FHI 360

  • Steve Sortijas, MPH · FHI 360

  • Fidèle Ngabo, MD, MPH · Ministry of Health, Rwanda

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-10-31
Completion
2011-12-31

Countries

  • Rwanda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01115361 on ClinicalTrials.gov